Table 3.

Case report timeline

Timeline	Remarks	Specific treatment (daily dosage)
September 25, 2022	2 background illnesses: CD and HIV	Background medication: Azathioprine 50 mg × 2 + mesalazine 2000 mg × 2. Dolutegravire 50 mg × 1. Emtricitabine + Tenofovir disoproxil 445 mg × 1
	PE	Oxygen (99.50%) 3 L/min (if SpO2 is < 95%). Ketorolac trometamol 30 mg (once). Calcium nadroparin 0.6 mL × 2. Amoxicilline + clavulanic acid 1200 mg × 4
September 27, 2022	CMV DNA detected: 420 copies/mL	Ibuprofen 400 mg (if > 38.5 °C). TMP + SMX 1920 mg × 3. Prednisolone 40 mg Ã-2 to 40 mg × 1 to 20 mg × 1
	EBV DNA detected: 13640 copies/mL P. jirovecii DNA detected Ct value: 25.79
September 30, 2022	Candida Ag (mannans): Positive	Fluconazol 150 mg × 1 to 300 mg × 1
October 14, 2022	New fever episode/sepsis	Azathioprine was suspended. Treatment of pneumocystosis (TMP + SMX and prednisolone) finished. Piperacillin + tazobactame 4500 mg × 4. Amikacine 250 mg × 2
October 17, 2022	E. coli detected in microbiological blood sample cultures	Piperacillin + tazobactame 4500 mg × 4. Amikacine 250 mg × 2. Paracetamol 1000 mg × 1 (if > 38.5 °C)
October 18, 2022	E. faecium detected in microbiological urine sample cultures
October 19, 2022	No clinical effect in terms of sepsis	Linezolid 600 mg × 2 added to antibiotic therapy
October 26, 2022	Acute conjunctivitis of both eyes	Hypromellose 1 mg × 4
October 31, 2022	Overall conditions stabilized

Ag: Antigen; CD: Crohn’s disease; CMV: Cytomegalovirus; Ct: Cycle threshold; DNA: Deoxyribonucleic acid; E. coli: Escherichia coli; E. faecium: Enterococcus faecium; EBV: Epstein Barr virus; HIV: Human immunodeficiency virus; P. jirovecii: Pneumocystis jirovecii; PE: Pulmonary embolism; SpO₂: Oxygen saturation; TMP + SMX: Trimethoprim + sulfamethoxazole.